From on Medscape

Coverage from the

European Atherosclerosis Society (EAS) 2021

May 30 - June 02, 2021; Virtual

May 30 - June 02, 2021 Virtual
  • EAS 2021 Do Anti-ApoA-1 Antibodies Link Fatty Liver Disease and CVD? Anti-ApoA-1 antibodies appear to be common in patients with NAFLD and may drive both fat deposits and pro-inflammatory effects in liver cells, although it remains to be seen whether they can be targeted.

Conference News

News from EAS 2020

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resource